Skip to main content
. 2011 Dec 20;33(4):531–537. doi: 10.1093/eurheartj/ehr460

Figure 1.

Figure 1

Cumulative incidence of atrial fibrillation according to study group. Shown is the incidence of atrial fibrillation in the placebo and rosuvastatin groups. The P-value was calculated using a likelihood ratio test of the effect of rosuvastatin, using a proportional hazards model.